首頁
Degron Therapeutics

6月 2026Degron Therapeutics的市場佔有率分析

degron therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (mgd) drugs. degron has assembled a team of world-class executives and scientific leaders, bringing its scientific excellence to the identification and validation of disease targets, particularly those undruggable by conventional small molecule inhibitors, and novel selective mgd compounds to meet unmet medical needs in all therapeutic areas.

行業: N/A

域名degrontx.com

成立年份2021

僱員51 - 200

年度營收$1M - $2M

Degron Therapeutics

Degron Therapeutics（包含公司地區）

degrontx.com

查看更多網站流量與參與度資訊

Degron Therapeutics截至 6月 2026 的總收入為 1M - 2M

Degron Therapeutics 熱門網域產生的總收入

Degron Therapeutics 熱門網域 3 年內的總收入

Degron Therapeutics 熱門網域的總收入

degrontx.com1M - 2M

透過銷售情報查看更多內容

Degron Therapeutics的熱門網域總造訪量

了解Degron Therapeutics市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

degrontx.com2.2K

透過銷售情報查看更多內容

Degron Therapeutics的熱門網域平均造訪時長

分析Degron Therapeutics參與度指標。

過去 3 個月平均造訪時長

子公司細目

degrontx.com00:00:36

透過銷售情報查看更多內容

Degron Therapeutics的熱門網域平均頁面瀏覽量

了解Degron Therapeutics如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

degrontx.com2.37

透過銷售情報查看更多內容

Degron Therapeutics按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Degron Therapeutics

这些是Degron Therapeutics顶级域名使用的行业网站技术

付費廣告 (2)

Baidu Ads

音訊視訊媒體 (1)

Flowplayer

內容管理系統 (1)

Wix

行動裝置 (1)

Meta Viewport

更多技術

2

檢視所有

新聞與訊號來自Degron Therapeutics

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Merck partners with Degrontx.Merck partners with China's Degron, Medimscience on molecular glue, autoimmune programs.

新聞Degrontx is developing molecular glues for undisclosed immune-mediated conditions on Sep 1st '25.Still, Shanghai-based Degron will go up against a giant in the immunology arena, with Novartis in September 2025 inking a $5.7 billion agreement with Monte Rosa Therapeutics to develop molecular glues for undisclosed immune-mediated conditions.

新聞Degrontx receives financing of $40M in Series A1.Degron Therapeutics has secured a $40 million Series A extension as investor interest continues building around targeted protein degradation technologies and next-generation cancer therapies aimed at previously "undruggable" disease targets.